Monitoring Breast Cancer Care Quality at National and Local Level Using the French National Cancer Cohort.


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
10 2022
Historique:
received: 22 04 2022
revised: 13 05 2022
accepted: 17 05 2022
pubmed: 25 6 2022
medline: 28 9 2022
entrez: 24 6 2022
Statut: ppublish

Résumé

The French National Cancer Institute has developed, in partnership with the French National Authority for Health, breast cancer-specific Care Quality, and Safety Indicators (BC QIs). With regard to the most common form of cancer, our aim is to support local and national quality initiatives, to improve BC pathways and outcomes, reduce heterogeneity of practice and regional inequities. In this study, we measure the BC QIs available in the French National medico-administrative cancer database, the French Cancer Cohort, for 2018. BC QIs are developed according to the RAND method. QIs are based on good clinical practice and care pathway recommendations. QI computation should be automatable without any additional workload for data collection. They will be published annually for all stakeholders, and especially hospitals. Finally, ten feasible and pertinent QIs were selected. In France, BC care was found to be close to compliance with most QIs: proportion of patients undergoing biopsy prior to first treatment (94.5%), proportion of patients undergoing adjuvant radiotherapy after breast-conserving surgery for BC (94.5%), proportion of women undergoing radiotherapy within 12 weeks after surgery and without chemotherapy (86.2%), proportion of DCIS patients undergoing immediate breast reconstruction (54.3%) and proportion of women with NMIBC undergoing breast reintervention (14.4%). However, some are still far from their recommended rate. In particular, some QIs vary considerably from one region, or one patient, to another. Each result needs to be analyzed locally to find care quality leverage. This will strengthen transparency actions aimed at the public.

Identifiants

pubmed: 35750594
pii: S1526-8209(22)00096-9
doi: 10.1016/j.clbc.2022.05.006
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e832-e841

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Disclosure The authors declare that they have no conflict of interest.

Auteurs

Sophie Houzard (S)

Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France. Electronic address: shouzard@institutcancer.fr.

Emilie Courtois (E)

Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France.

Christine Le Bihan Benjamin (C)

Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France.

Marie Erbault (M)

Quality and Safety Care Improvement Department, French National Authority for Health, Saint-Denis La Plaine CEDEX, France.

Laurent Arnould (L)

Department of Pathology, GF Leclerc Cancer Centre, Dijon, France.

Emmanuel Barranger (E)

Department of Surgery, Antoine Lacassagne Cancer Centre, Nice, France.

Florence Coussy (F)

Department of Medical Oncology, Institute Curie, Paris, France.

Benoît Couturaud (B)

Department of Surgery, Institute Curie, Paris, France.

Bruno Cutuli (B)

Department of Radiation Oncology, Courlancy Cancer Clinic, Reims France.

Patricia de Cremoux (P)

Saint Louis University Hospital, Paris France.

Pia de Reilhac (P)

Medical Gynecology, Nantes, France.

Chantal de Seze (C)

Oise Cancer Screening Association, Compiègne, France.

Aude-Marie Foucaut (AM)

Education and Health Promotion Laboratory UR 3412, Université Sorbonne Paris Nord, Bobigny, France.

Anne Gompel (A)

Gynecological Surgery and Oncology, Reproductive Medicine, Cochin University Hospital, Paris, France.

Stéphane Honoré (S)

Pharmaceutical Expertise and Biomedical Research, La Timone University Hospital, Marseille Cedex 5, France.

Anne Lesur (A)

Department of Senology, Lorraine Cancer Institute - Alexis Vautrin, Vandœuvre-lès-Nancy Lorraine Cancer Institute - Alexis Vautrin, Vandoeuvre Les Nancy, France.

Carole Mathelin (C)

Department of Senology, Strasbourg University Hospital, Strasbourg, France.

Laurent Verzaux (L)

Radiology Practice, Le Havre, France.

Philippe-Jean Bousquet (PJ)

Survey Data Science and Assessment Division, National Cancer Institute, Boulogne Billancourt, France; Aix Marseille University, INSERM, IRD, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH